Zoetis expands presence in Australia with Melbourne manufacturing site acquisition

349
Image supplied.

Animal health company Zoetis has acquired a 21-acre manufacturing site in Melbourne, doubling its manufacturing footprint and setting the stage for enhanced capabilities in developing and manufacturing vaccines for various animals, including sheep, cattle, dogs, cats, and horses.

This significant expansion aims to cater to the growing demand for vaccines, which currently sees 130 million doses produced annually in Australia, the company said in a media release.

The livestock sector, contributing $67 billion to Australia’s annual turnover and employing 428,000 people, underscores the importance of maintaining healthy animals for both economic and food security reasons.

Kristin Peck, CEO of Zoetis, expressed enthusiasm about the increased investment in Australia, emphasising the company’s dedication to supporting farmers and veterinarians in their efforts to keep animals healthy and productive.

“Australia’s livestock sector is highly regarded around the world, and Zoetis is proud to help the region’s livestock farmers be part of a climate solution as they increase productivity, health and welfare outcomes that can have a positive impact on the planet,” Peck noted.

Meanwhile, Lance Williams, senior vice president and Zoetis’ ANZ lead, echoed Peck’s sentiments, underscoring the significance of local manufacturing and Zoetis’ commitment to Australian producers.

“We’re pleased to play an important role in supporting a healthy livestock sector in Australia, and helping Australian producers remain productive and profitable,” said Williams.

The Melbourne site, located in the suburb of Parkville, has a rich history dating back to the 1930s when it contributed to the development of vaccines for black disease in sheep.

Since 2004, Zoetis has operated at the site under a long-term lease, producing a range of vaccines for various animal species including cattle, sheep, horses, dogs, cats, and pigs.

This acquisition builds upon Zoetis’ previous investment in Australia, including the acquisition of Jurox in 2022, which provided the company with a second manufacturing site in the NSW Hunter Valley.

Zoetis’ expanded footprint at the Parkville site is expected to grow significantly in the years ahead, further solidifying its position as a key player in Australia’s animal health industry.

In 2023, Zoetis reported sales of $484 million in Australia, representing a 17 per cent increase from the previous year.